{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:01Z","timestamp":1786119661547,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/cco.0b013e32833ed848","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T08:14:55Z","timestamp":1283328895000},"page":"642-645","source":"Crossref","is-referenced-by-count":23,"title":["Front-line management of diffuse large B cell lymphoma"],"prefix":"10.1097","volume":"22","author":[{"given":"Fernando","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210128","first-page":"3024","article-title":"Chemotherapy of malignant lymphoma with Adriamycin","volume":"33","author":"Gottlieb","year":"1973","journal-title":"Cancer Res"},{"key":"R2-17-20210128","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"key":"R3-17-20210128","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-98-3-304","article-title":"Diffuse aggressive lymphoma: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy","volume":"98","author":"Fisher","year":"1983","journal-title":"Ann Int Med"},{"key":"R4-17-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1200\/JCO.1983.1.2.91","article-title":"Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)","volume":"1","author":"Skarin","year":"1983","journal-title":"J Clin Oncol"},{"key":"R5-17-20210128","first-page":"41","article-title":"MACOP-B chemotherapy for malignant lymphomas and related conditions:1987 update and additional observations","volume":"25","author":"Connors","year":"1988","journal-title":"Semin Hematol"},{"key":"R6-17-20210128","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"R7-17-20210128","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"R8-17-20210128","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R9-17-20210128","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsed or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"R11-17-20210128","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1200\/JCO.2004.05.926","article-title":"The limits of limited stage lymphoma","volume":"22","author":"Miller","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-17-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R13-17-20210128","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"R14-17-20210128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"R15-17-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"R16-17-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"R18-17-20210128","first-page":"8","article-title":"Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-Cell lymphoma (DLBCL).","volume":"102","author":"Habermann","year":"2003","journal-title":"Blood"},{"key":"R19-17-20210128","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"R20-17-20210128","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-17-20210128","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32833ed848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:41:38Z","timestamp":1786041698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201011000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32833ed848","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}